Efferocytosis in the tumor microenvironment

Thomas A. Werfel 1 · Rebecca S. Cook 1,2,3,4

Received: 5 June 2018 / Accepted: 3 August 2018 / Published online: 5 September 2018
© The Author(s) 2018

Abstract
Within the course of a single minute, millions of cells in the human body will undergo programmed cell death in response to physiological or pathological cues. The diminished energetic capacity of an apoptotic cell renders the cell incapable of sustaining plasma membrane integrity. Under these circumstances, intracellular contents that might leak into the surrounding tissue microenvironment, a process referred to as secondary necrosis, could induce inflammation and tissue damage. Remarkably, in most cases of physiologically rendered apoptotic cell death, inflammation is avoided because a mechanism to swiftly remove apoptotic cells from the tissue prior to their secondary necrosis becomes activated. This mechanism, referred to as efferocytosis, uses phagocytes to precisely identify and engulf neighboring apoptotic cells. In doing so, efferocytosis maintains tissue homeostasis that would otherwise be disrupted by normal cellular turnover and exacerbated further when the burden of apoptotic cells becomes elevated due to disease or insult. Efferocytosis also supports the resolution of inflammation, restoring tissue homeostasis. The importance of efferocytosis in health and disease underlies the increasing research efforts to understand the mechanisms by which efferocytosis occurs, and how a failure in the efferocytic machinery contributes to diseases, or conversely, how cancers effectively use the existing efferocytic machinery to generate a tumor-tolerant, immunosuppressive tumor microenvironment. We discuss herein the molecular mechanisms of efferocytosis, how the process of efferocytosis might support a tumor ‘wound healing’ phenotype, and efforts to target efferocytosis as an adjunct to existing tumor treatments.

Keywords Efferocytosis · Apoptotic cell death · MerTK · Phosphatidyl serine, macrophage · Tumor microenvironment

Introduction
Dying cells are present in most tissues, due to both physiological and pathological cues. Cell death is a key biological process used during developmental stages, when tissues are being formed and shaped. For example, the epidermal webbings that exist between the digits of the developing forelimb of a mammal are removed through the process of apoptosis, forming the articulation of each independent digit [1]. During mammary gland morphogenesis, the ductal epithelium forms initially as a solid cord, but becomes canalized through the process of selective apoptosis of centrally located mammary epithelial cells (MECs) [2]. Even within a fully mature animal, cellular turnover is seen in most tissues, as this process is responsible for removing aged, expired, or unwanted cells. In some circumstances, physiologically induced cell death can occur in a dramatic wave of widespread apoptosis throughout the tissue. For example, the milk-producing MECs that populate the breast during pregnancy and then terminally differentiate during lactation are energetically expensive to maintain, and thus are culled from the breast upon weaning of offspring through the induction of programmed cell death [3]. In rodent models, it is estimated that the widespread cell death characteristic of post-lactational involution removes up to 90% of all MECs in the mammary gland within 7–10 days, representing a powerful model to examine the causes and consequences of cell death within a physiological context. The physiological...
Mechanisms of efferocytosis

The process of clearing dying cells from tissue occurs in a series of coordinated and sequential molecular events that eventually result in phagocytosis of the dying cell [23]. Early in the process of apoptosis, the dying cell secretes biochemical mediators, referred to as “find-me” signals, to recruit phagocytes to their proximity (Fig. 1). Find-me signals enable the rapid recognition of dying cells by phagocytes at

involvement, resulting in severe mammary gland inflammation (mastitis), tissue damage, and peri-ductal scarring [12]. MerTK is similarly required by RPECs for engulfment of photoreceptor outer segments that are diurnally released [17]. In the testis, MerTK loss causes inflammation (retinitis pigmentosa), tissue damage, and in many cases, age-related blindness [18]. In the testis, MerTK-deficient Sertoli cells are incapable of ingesting the dying germ cells generated during spermatogenesis, predisposing male MerTK-deficient mice to testicular inflammation and decreased fertility [19]. Thus, efferocytosis prevents inflammation in tissues where dying cells are present, in large part by preventing the secondary necrosis of dying cells.

Once membrane integrity is lost, cytotoxic and nuclear contents released by the dying cell will inform neighboring cells, particularly macrophages and DCs [20], that danger may be present. Because necrosis is often the result of infection or injury, the released cytoplasmic and nuclear contents represent danger-associated molecular patterns (DAMPs) that induce inflammatory cytokine and chemokine expression from neighboring cells, which rapidly mobilize both innate and adaptive immune responses, in an effort to limit the injurious process at hand [21]. Thus, efferocytosis prevents unwanted inflammation by engulfing the apoptotic cell before secondary necrosis allows leakage of DAMPs into the extracellular space.

However, efferocytosis modulates immunity well beyond the prevention of inflammation. Following engulfment of apoptotic cells, phagocytes are instructed to produce anti-inflammatory cytokines such as transforming growth factor (TGF)-β and interleukin (IL)-10, while actively dampening their expression of pro-inflammatory cytokines such as IL-12 and tumor necrosis factor (TNF) [22]. Immunomodulatory cytokine regulation occurs both in professional and in non-professional phagocytes and is coupled to the efferocytic process. This molecular coupling ensures that efferocytosis is more than “immunologically silent,” but rather actively enforces immune tolerance, wound healing, and homeostasis. Thus, it is not surprising that aberrations in the process of efferocytosis might produce a variety of pathological consequences, or conversely, that tumors might capitalize from the tolerogenic nature of efferocytosis to support cancer progression and evade immune surveillance. Here, we review the basic mechanisms of efferocytosis, its role in the tumor microenvironment, and potential treatment strategies to combat the protumorogenic effects of efferocytosis in the TME.

Mechanisms of efferocytosis

The process of clearing dying cells from tissue occurs in a series of coordinated and sequential molecular events that eventually result in phagocytosis of the dying cell [23]. Early in the process of apoptosis, the dying cell secretes biochemical mediators, referred to as “find-me” signals, to recruit phagocytes to their proximity (Fig. 1). Find-me signals enable the rapid recognition of dying cells by phagocytes at

Loss of efferocytic capabilities within a given tissue can severely impair tissue homeostasis, resulting in inflammation-induced tissue damage and decreased tissue function. For example, mice deficient for MerTK, a receptor tyrosine kinase (RTK) required by MECs for binding to and engulfing apoptotic cells, are incapable of clearing the widespread burden of apoptotic cells from the mammary gland during post-lactation

Regardless of the causes of apoptosis, or the number of apoptotic cells generated within a tissue, it is remarkable that apoptotic cell death proceeds without inducing inflammation, particularly considering what happens to dying cells in the absence of any external influence. Left to its own devices, a dying cell will ultimately lose membrane integrity, leaking cytoplasmic and nuclear contents into the tissue microenvironment [5]. However, it is quite rare under physiological circumstances that an apoptotic cell would lose its membrane integrity and leak its highly inflammatory intracellular contents into tissues, a process referred to as secondary necrosis. The reason for the scarcity of secondary necrosis under physiological conditions, despite the constant burden of apoptotic cells, is that phagocytic cells residing within each tissue, or recruited to the tissue, are adept at recognizing and engulfing apoptotic cells before apoptotic cell membrane integrity is lost. The phagocytic engulfment of apoptotic cells is a process termed efferocytosis [6, 7].

Efferocytosis can be accomplished by professional, non-professional, and specialized phagocytes, and each plays a necessary role in maintaining tissue homeostasis in the event of local cell death. Macrophages and dendritic cells (DCs) are professional phagocytes that are found in most tissues and are the most commonly studied of the efferocytes. Macrophages of the spleen and liver are responsible for clearing expired erythrocytes from the circulating blood [8], microglia (a specialized central nervous system macrophage) clear dying neurons from the central nervous system [9], and resident lung macrophages are critical for removal of dying alveolar epithelial cells [10]. However, non-professional phagocytes are capable of the important homeostatic role of efferocytosis as well. For example, MECs in the mammary gland are critical for efferocytosis during the earliest stages of post-lactational involution [11, 12]. Similarly, lung airway epithelial cells (LAECs) are capable of ingesting apoptotic neighboring LAECs [10]. Fibroblasts [13], endothelial cells [14], Sertoli cells of the testis [15], and retinal pigment epithelial cells (RPECs) [16] are other known examples of non-professional phagocytes with key roles in sustaining tissue homeostasis and health through efferocytosis.

Loss of efferocytic capabilities within a given tissue can severely impair tissue homeostasis, resulting in inflammation-induced tissue damage and decreased tissue function. For example, mice deficient for MerTK, a receptor tyrosine kinase (RTK) required by MECs for binding to and engulfing apoptotic cells, are incapable of clearing the widespread burden of apoptotic cells from the mammary gland during post-lactation
the earliest stages of apoptosis, which is an important aspect of rapid apoptotic cell clearance. Indeed, efferocytosis can proceed even when caspase-mediated apoptosis is not yet fully executed to completion. Four “find-me” signals have been identified thus far: nucleotides (e.g., adenosine triphosphate [ATP]) and CX3CL1 as “Find me” signals that biochemically attract monocytes by engaging the P2Y2 and CX3CR1 receptors, respectively. Lactoferrin has potent and specific anti-migratory effects on neutrophils and is released by apoptotic cells as a “Keep out” signal for inflammatory cells. Phagocytes must preferentially identify apoptotic cells for efferocytosis while leaving healthy cells unengulfed. Apoptotic cells display PtdSer lipid on the outer leaflet of the cell membrane, which is recognized by phagocytes either directly through BA11, TIM-4, or Stabilin 2 or indirectly through the αvβ3-MFG-E8 or MerTK-Gas6 bridging combinations. In addition to lower PtdSer outer-leaflet exposure, healthy cells express “Don’t eat me” signals such as CD47 and CD31 which prevent phagocyte activation and engulfment. Apoptotic debris are engulfed via LC3-associated phagosomes which fuse with lysosomes and efficiently degrade cellular contents of the apoptotic cell. The production of fatty acids such as 25-hydroxysterol result in the activation of nuclear receptors and transcriptional regulators, PPAR and LXR, whose activation promotes transcription of pro-efferocytic machinery (MerTK, Gas6, Rac1) and immunosuppressive cytokines (TGF-β1, IL-10, IL-13)
While “find-me” signals help recruit phagocytes within close proximity of dying cells, “eat-me” signals serve as specific cell surface markers that enable phagocytes to uniquely identify apoptotic cells once the phagocyte arrives on site (Fig. 1b). Once in range, phagocytes recognize the “eat-me” signals displayed on the apoptotic cell. The most heavily studied “eat-me” signal is phosphatidylserine (PtdSer), a phospholipid normally localized to the inner leaflet of the plasma membrane of healthy cells. Upon initiation of apoptosis, PtdSer is rapidly translocated to the plasma membrane exterior leaflet of the apoptotic cell [28]. It is estimated that PtdSer exposure increases approximately 300-fold within 1–2 h after initiation of apoptosis, flagging the apoptotic cell for engulfment by a neighboring phagocyte [29].

Multiple engulfment receptors expressed by phagocytes are responsible for binding to PtdSer on the dying cell (Fig. 1b). For example, brain angiogenesis inhibitor 1 (BAI1) [30], T cell immunoglobulin and mucin domain-containing-4 (TIM-4) [31], and Stabilin-2 [32] bind directly to PtdSer, allowing phagocytes that express BAI1, TIM-4, or Stabilin-2 to bind dying cells directly. Alternatively, PtdSer can interact with a ‘bridging ligand’ that simultaneously binds to receptors expressed upon a phagocyte. For example, the soluble bridging ligands growth arrest specific-6 (Gas6) [33], Protein S (ProS1) [34], Galectin-3 (Gal3) [35], Tubby and Tubby-like Protein-1 (TULP1) [36] bind to PtdSer on the apoptotic cell and simultaneously bind to the MerTK on the phagocyte. Gas6 also bridges the apoptotic cell to the MerTK-related RTKs Axl and Tyro3, which are expressed by macrophages and DCs [37]. Lactadherin, also known as milk fat globule-EGF factor 8 (MFG-E8) bridges PtdSer of the dying cell to αvβ3 and αvβ3 integrins expressed on the phagocyte [38]. Scavenger receptors, lectins, and complement receptors also serve as PtdSer-binding molecules expressed by phagocytes that aid in recognition of apoptotic cells [39].

However, PtdSer recognition and binding are not sufficient to drive efferocytosis of an apoptotic cell. For example, it is possible for a cell to expose PtdSer on its outer surface without inducing efferocytosis [29]. In certain scenarios, this is due to the need for co-stimulation with second messengers such as calreticulin [40, 41], although the exact mechanisms dictating the need for costimulation remain inconclusive. It is also proposed that, while phagocytes scan for apoptotic cell ‘eat me’ signals, phagocytes simultaneously scan for ‘don’t eat me’ signals (Fig. 1b). Two well-studied ‘don’t eat me’ markers include CD47, a ubiquitously expressed integrin- and thrombospondin-binding protein, and CD31, an integrin-activating protein expressed by hematopoietic lineages. Both CD31 and CD47 inhibit the engulfment of healthy cells that otherwise might express PtdSer on their surface, such as platelets and endothelial cells [42, 43]. This function is particularly important, given that PtdSer, ProtS, and Gas6 each have roles in platelet aggregation and vascular wound repair [44]. Thus, the recognition of apoptotic cells for clearance involves a complex interplay between ‘find me,’ ‘eat me,’ and ‘do not eat me’ signaling.

Upon recognition and tethering of apoptotic cells to the phagocyte, cytoskeletal rearrangement within the phagocyte induce pseudopodia extension to surround the apoptotic cell in what is referred to as the ‘phagocytic cup,’ eventually engulfing the membrane-encapsulated dying cell into what is known as the phagosome. The precise intracellular molecular signaling pathways initiating cytoskeletal rearrangements for the formation of the phagocytic cup and the phagosome are still being elucidated. However, it is clear that multiple signaling pathways converge on Rac1, a small GTPase that serves as a potent activator of cytoskeletal dynamics and that is required for efferocytosis [38]. Inhibition of Rac1 signaling impairs engulfment of dying lung epithelial cells by LAECs [45] and blocks engulfment of photoreceptor outer segments by RPECs in the retina [46].

Receptors expressed by the phagocyte that bind to the bridging molecules Gas6, ProtS, and MFG-E8 have been shown to engage Rac1 through the guanine nucleotide exchange factor (GEF) complex formed by the two proteins ELMO1 and DOCK180 [47]. However, ELMO/DOCK180 does not bind directly with MerTK, integrin αvβ3, or the other bridging molecule receptors. In the case of MerTK, its tyrosine kinase activity results in tyrosine phosphorylation of SH2 and SH3 domains in its cytoplasmic tail, generating binding sites for the adaptor molecule CrkII, which recruits ELMO/DOCK180 to MerTK [48]. Once there, it is unclear how the GEF activity of ELMO/DOCK180 is activated. Similarly, the PtdSer-binding protein BAI1 activates the GEF activity of ELMO/DOCK180, also through machanisms that are incompletely understood, but unlike the bridging molecule receptors, BAI1 interacts directly with ELMO/DOCK180 [30].

Post-engulfment, a host of pro-efferocytic and wound-healing signaling events are initiated and lead to immunosuppression, altered immunometabolism, M2-like macrophage polarization, and wound healing, profoundly impacting the resultant phenotype of the local tissue microenvironment (Fig. 1c). The nuclear receptor (NR) family of transcriptional factors, specifically liver X receptor (LXR)-α and peroxisome proliferator-activated receptor (PPAR)-γ, become activated in response to efferocytosis, and play a key role in shaping the efferocytosis-induced anti-inflammatory phenotype [49]. However, the mechanism(s) by which LXRs and PPARγ become activated during efferocytosis have only recently been uncovered and are very much dependent upon trafficking and processing of the engulfed apoptotic cell within the phagosome. Intriguingly, components of the autophagy machinery have been identified on phagosomes containing apoptotic cells and are essential for apoptotic cell processing and subsequent immunomodulation. Specifically, LC3-associated phagocytosis (LAP), a process in which the hallmark protein
of the autophagy machinery, LC3, is conjugated to the phagosome, provides a mechanistic link between engulfment of the dying cells and LXRα/PPARγ activation [50]. Although LAP uses machinery associated with autophagy, LAP is distinct from canonical and non-canonical forms of autophagy. There is a growing body of evidence from untransformed tissues showing that LAP is required for effective clearance of dying cells [51].

During LAP, the autophagy-related proteins LC3, Vsp34, Vsp15, Beclin, and UVRAG, but not the autophagy-related proteins ULK1 or Atg7, are recruited to the phagosomal surface rapidly after AC engulfment, generating what is known as a ‘LAP’osome [51]. The protein Rubicon, which largely inhibits autophagy, is also required during LAP [52]. LAPosome formation is necessary for phagosomal trafficking to, and fusion to, lysosomes, where the dying cell corpse is degraded by acidic proteases, lipases, and nucleases of the lysosome, and where cholesterol derived from the dying cell are either partitioned for efflux, or esterified then hydrolyzed by lysosomal acid lipase into 25-hydroxysterol and 27-hydroxysterol, the ligands responsible for activation of LXRα [49]. The digested fatty acids derived from the dying cell produce the ligands responsible for activation of PPARγ [53]. Together, ligand-activated LXRα/PPARγ activate the transcription of anti-inflammatory cytokine-encoding genes, including Tgfb1, Il10, and Il13. Moreover, LXRα and PPARγ upregulate transcription of genes encoding the effecrocytic machinery, including those encoding MerTK, Tyro3, Axl, MFG-E8, Gas-6, and Rac1, while enhancing expression of lysosomal components, and genes encoding factors required to efficiently dispatch the engulfed and digested components, including the cholesterol efflux proteins ABCA1 and ABCG1 [54–56].

Similar to what is seen in mice defective for effecrocytosis, mice with genetic aberrations that interfere with LAP are prone to uncontrolled inflammation and, in some cases, symptoms of autoimmunity. The importance of lysosomal degradation of the ingested cell corpse can be illustrated by observations of phagocytes lacking lysosomal DNAse II, which inefficiently degrade DNA from the engulfed corpse, thus allowing the accumulated cytoplasmic DNA fragments to activate cytoplasmic DNA sensors that trigger innate immunity and inflammation [57]. Failure to properly digest cholesterol within the lysosome leads to the precipitation of toxic cholesterol salts within cytoplasmic compartments of the phagocyte, decreasing phagocytic cell survival, and increasing inflammation [58]. Phagocytes deficient for lysosomal acid lipase fail to activate LXRα following effecrocytosis, impairing expression of anti-inflammatory cytokines, and also decreasing expression of genes encoding the effecrocytic machinery, cholesterol efflux pathways, and phagocytic cell survival [59]. Thus, LAP sits at the crossroads of effecrocytosis and the resultant anti-inflammatory response.

Once the apoptotic cell is engulfed, the phagocyte now carries an excess of lipids, cholesterol, carbohydrates, proteins, and nucleic acids, dramatically altering the metabolic load of the phagocyte, and potentially contributing to mitochondrial oxidative stress, a highly pro-inflammatory event. The phagocyte adapts to the metabolic emergency created by effecrocytosis in part by increasing Drp1-mediated mitochondrial fission at the mitochondrial associated membrane (MAM), thus allowing Ca2+ release into the cytoplasm, which has two important effects [60]. First, Ca2+ release lowers mitochondrial membrane potential, relieving mitochondrial oxidative stress. Second, Ca2+ aids in LAPosomal trafficking to and fusion with lysosomes. Phagocytes also increase mitochondrial biogenesis, increase fatty acid oxidation, and increase oxidative phosphorylation (OxPhos) to meet the shifting metabolic requirements of effecrocytosis [49]. Interestingly, the capacity for a cell to engage and upregulate OxPhos and mitochondrial fission influences not only its survival, but also its future success as an effecrocyte and its ability to produce an anti-inflammatory phenotype.

**Efferocytosis in the tumor microenvironment**

Cell death is a common event in solid tumors during malignant progression, and increases further with cytokotoxic treatment. The type of cell death undergone (i.e., apoptosis, necrosis, necroptosis, or pyroptosis) and subsequent mechanisms of corpse clearance have a profound impact on the immune phenotype within the TME (Fig. 2). Clearance of dying cell corpses in the TME via effecrocytosis is canonically an immunosuppressive phenomenon [61]. In contrast necrosis and secondary necrosis of uncleared apoptotic cells promotes a pro-inflammatory landscape and anti-tumor immunity. Interestingly, clearance of live tumor cells by phagocytosis may also serve as a pro-inflammatory process. For example, inhibition of the “do not eat-me” CD47-SIRPα interaction between tumor cells and phagocytic macrophages leads to an anti-tumor immune response characterized by the presence of CD8+ cytotoxic T lymphocytes and absence of FOXP3+ immunosuppressive T regulatory cells [62, 63].

Efferocytosis creates an immunosuppressive phenotype within tumors through a coordinated series of signaling events involving multiple compartments of the tumor milieu [61, 64]. Efferocytosis limits the presence of pro-inflammatory DAMPs released by secondary necrotic, uncleared corpses. Consequently, cytokine production is shifted from what might otherwise have been immunostimulatory (e.g., TNF, IFN, IL-12) to immunosuppressive (e.g., IL-4, IL-10, IL-13, and TGF-β) when effecrocytosis is functional in the TME. During effecrocytosis, tumor-associated macrophages (TAMs) are polarized toward an M2-like wound healing phenotype through metabolic signaling downstream of PPARγ and
LXRα. Anti-inflammatory and inflammation-resolving cytokines produced upon efferocytosis recruit FOXP3+ regulatory T cells, which potently suppress the effector functions of CD4+ and CD8+ effector T cells within the TME. Further, efferocytosis upregulates MerTK, Axl, and Tyro3 expression and activity on tumor macrophages and DCs, promoting polarization towards an immunosuppressive phenotype. Because DCs and macrophages are important antigen presenting cells that lie at the interface of innate and adaptive immunity, the efferocytosis-mediated shift in DC and macrophage phenotypes result in decreased antigen cross presentation to T cells, decreased T cell clonal expansion, and impaired development of antigen-dependent anti-tumor immunity. Thus, the cumulative effect of efferocytosis serves to limit tumor inflammation and anti-tumor immunity and suggests that efferocytosis is an underappreciated immune checkpoint, perhaps one that might be therapeutically targeted in the setting of cancer.

Interestingly, results linking efferocytosis to cancer progression are increasing. For example, blockade of efferocytosis using Annexin V to block PtdSer from interacting with the efferocytosis machinery of phagocytes sufficiently reduces tumor progression and metastasis [65, 66]. Further, the efferocytosis receptor MerTK correlates with poor survival in numerous human cancers, as does its PtdSer bridging ligand Gas6 [64, 67–72]. Notably, α,β3 integrin and its PtdSer bridging ligand MFG-E8 are dysregulated in preclinical models of prostate and triple negative breast cancers [73, 74]. The PtdSer receptor TIM4 has garnered much attention as a potential cancer vaccine adjuvant [75–77]. Although a growing body of evidence supports the idea that efferocytosis in the tumor microenvironment increases tumor progression, it remains to be seen whether these molecules exhibit their pro-tumorogenic effect primarily through efferocytosis, per se, or if the pro-tumorogenic impact of each molecule is multi-faceted. For example, recent findings indicate roles for MerTK [78, 79], MFG-E8 [73], and PtdSer [65, 66] in the development and progression of neoplasia specific to their effectorcic functions. However, MFG-E8 and Gas6 are also known to increase macrophage polarization independently of efferocytosis [80, 81]. Thus, dissecting the impact of efferocytosis from other effects of Gas6 or MFG-E8 signaling might be difficult.

A series of studies implicated oncogenic roles for MerTK where its expression correlated with poor prognosis and chemoresistance in solid tumors and blood cancers [64, 67–69, 71, 72, 82]. Several studies show that tumor associated macrophages use MerTK signaling to produce a more aggressive and tolerogenic tumor microenvironment. For example, tumors grew more slowly and were poorly metastatic when MerTK is absent from the leukocyte cellular compartment [78]. Importantly, transplantation of MerTK−/− bone marrow into wild-type mice decreased tumor growth and altered cytokine production whereas transplantation of wild-type bone marrow had no such effects, strengthening the link to a leukocyte-specific role for the oncogenesis of MerTK. Interestingly, breast cancer progression is accelerated in the postpartum mammary gland, a microenvironment with widespread programmed cell death and high levels of efferocytosis [83–85]. Using both spontaneous and allografted mammary tumor models in fully immune-competent mice, it was shown that dying mouse mammary tumor cells, even those occurring in the context of post-lactational involution, are cleared through MerTK-dependent efferocytosis, which drives the robust induction of immunosuppressive cytokines IL-4, IL-10,
IL-13, and TGF-β [79]. Moreover, genetic ablation or pharmacologic inhibition of MerTK in these models reduced M2-like macrophages, decreased wound-healing cytokine production, and blocked formation of postpartum tumor metastases. These studies strongly suggest that MerTK-mediated efferocytosis promotes a wound-healing microenvironment that drives metastatic tumor progression during post-partum involution of the breast.

**Therapeutic targeting of efferocytosis in the setting of cancer**

The tolerogenic and anti-inflammatory impact of efferocytosis on the microenvironment of untransformed tissues is decidedly important to avoid tissue damage initiated by unrestrained inflammation. However, in the context of the tumor microenvironment, the anti-inflammatory phenotype generated by efferocytosis would be undesirable. Further, it is possible that the tolerogenic and anti-inflammatory phenotype generated by efferocytosis would be amplified under conditions in which tumor cell death was widespread, such as might be seen in response to cytotoxic, anti-cancer treatments. If all tumor cells were eliminated in response to cancer treatment, then the consequences of tumor cell apoptosis and efferocytosis would be a moot point. Instead, a significant proportion of solid tumors treated with targeted therapy, chemotherapy, or radiation do not exhibit pathological complete response (pCR) in the pre-surgical (neoadjuvant) setting, but rather exhibit partial response (PR) or stable disease (SD). Although in these cases of PR or SD the tumor is surgically excised following neoadjuvant treatment, lack of pCR is a strong predictor of tumor recurrence. Many molecular traits of tumor cells undoubtedly contribute to lack of pCR and the ensuing poor patient outcome, but it is critical to understand how efferocytosis might affect tumors following therapeutically induced tumor cell death, given that efferocytosis may endow immune tolerance to any tumor cells remaining in the post-neoadjuvant treatment setting.

PtdSer targeting shows efficacy in pre-clinical models of lung [86], breast [87], pancreatic [88], and brain tumors [89]. The anti-PtdSer antibody, Bavituximab, has been combined with current clinical standards-of-care in early phase II clinical trials for HER2-negative metastatic breast cancer and advanced non-small-cell lung cancer [90, 91]. In the pre-clinical studies, blockade of PtdSer using either Annexin V protein or anti-PtdSer mAb promoted anti-tumor immunity through induction of M1-macrophage polarization, increased dendritic cell maturation and antigen presentation, and increased presence of CD8+ cytotoxic T cells within the tumor microenvironment [86, 88, 89, 92]. As expected due to the role of PtdSer in efferocytosis, and the impact of efferocytosis on M2 macrophage polarization, anti-PtdSer antibodies also reduce M2-like tumor associated macrophages and alter cytokine expression profiles from immunosuppressive to immunostimulatory [92].

Several small molecular weight inhibitors have been developed that may have the potential to block efferocytosis in the cancer setting. These include the AXL inhibitor BGB324 (also known as R428), currently in a phase 1b study in erlotinib-sensitive and refractory patients with stage III and IV non-small cell lung cancer (NSCLC) [93], and the MerTK inhibitor UNC-2025 [94], which has been reported to block growth of melanoma, NSCLC [95], and other tumor models in preclinical studies [96]. However, these studies have been directed primarily at Axl- and MerTK-expressing cells within the tumor cell compartment, rather than in phagocytes of the tumor microenvironment, and clinical studies examining efferocytosis as an objective have not been reported. Preclinical studies using the MerTK inhibitor BMS-777607, a small molecule inhibitor that also targets the RTKs Met, Ron, Tyro3, and Axl [97], confirmed that efferocytosis can be blocked within highly apoptotic post-lactational mammary tumors [79]. Importantly, these studies confirmed that inhibition of efferocytosis was sufficient to halt tumor progression through blockage of efferocytosis-induced anti-inflammatory cytokines such as TGF-β and IL-10, and potentially through increased secondary necrosis and subsequent inflammation. Neutralizing antibodies that block TGF-β signaling confirmed the role of this immunosuppressive cytokine in efferocytosis-induced tumor progression in the setting of post-lactational involution of the mammary gland. A separate, elegant study confirmed the role of IL-10 in progression of mammary tumors in the setting of post-lactational involution [98]. In the context of therapeutically rendered tumor cell death, one study demonstrated that tumor-associated macrophages potently up-regulate MerTK following radiation-induced tumor cell killing and that loss of Mer, or inhibition of TGF-β (SM16) combined with radiation controlled post-radiation tumor progression to a greater extent that radiation alone [99]. Although these studies are pre-clinical, these findings support the idea that efferocytosis of apoptotic tumor cells favors tumor progression through production of anti-inflammatory and tolerogenic cytokines.

**Conclusion**

Clearance of apoptotic cells prevents and resolves inflammation, at the same time increasing immune tolerance to antigens derived from the apoptotic cells. While these results are beneficial in the setting of normal physiology, and in most cases of inflammation, apoptotic cell clearance can have deleterious consequences within the tumor microenvironment, potentially affecting the natural progression of the disease, and perhaps thwarting much of the benefit derived from cancer treatments that induce tumor cell death. Our increasing knowledge of the molecular pathways used
by phagocytes to engulf, traffic, and degrade apoptotic cells may reveal points of vulnerability for therapeutic targeting of efferocytosis. With this as the goal, it is possible that inhibition of efferocytosis in combination with cancer treatments might promote secondary necrosis in the tumor microenvironment, potentially increasing tumor-infiltrating lymphocytes capable of anti-tumor immunity and improving the clinical responses to treatments across a variety of cancers.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References
1. Milligan CE et al (1995) Peptide inhibitors of the ice protease family arrest programmed cell death of motoneurons in vivo and in vitro. Neuron 15(2):383–393
2. Richert MM et al (2000) An Atlas of Mouse Mammary Gland Development. J Mammary Gland Biol Neoplasia 5(2):227–241
3. Strange R et al (1992) Apoptotic cell death and tissue remodelling during mouse mammary gland involution. Development 115(1):49
4. Elmore S (2007) Apoptosis: A Review of Programmed Cell Death. Toxicol Pathol 35(4):495–516
5. Silva Manuel T (2010) Secondary necrosis: The natural outcome of the complete apoptotic program. FEBS Lett 584(22):4491–4499
6. deCathelineau AM, Henson PM (2003) The final step in programmed cell death: phagocytes carry apoptotic cells to the grave. Essays Biochem 39:105
7. Savill J, Fadok V (2000) Corpse clearance defines the meaning of cell death. Nature 407:784
8. Lutz HU (2004) Innate immune and non-immune mediators of erythocyte clearance. Cell Mol Biol (Noisy-le-grand) 50(2):107–116
9. Thanos S (1991) The Relationship of Microglial Cells to Dying Neurons During Natural Neuronal Cell Death and Axotomy-induced Degeneration of the Retinal. Eur J Neurosci 3(12):1189–1207
10. Vandiver RW, Henson PM, Douglas IS (2006) Burying the Dead. CHEST 129(6):1673–1682
11. Monks J et al (2008) Epithelial Cells Remove Apoptotic Epithelial Cells During Post-Lactation Involution of the Mouse Mammary Gland.1. Biol Reprod 78(4):586–594
12. Sandahl M et al (2010) Epithelial cell-directed efferocytosis in the post-partum mammary gland is necessary for tissue homeostasis and future lactation. BMC Dev Biol 10(1):122
13. Hermetet F et al (2016) Efferocytosis of apoptotic human papillomavirus-positive cervical cancer cells by human primary fibroblasts. Biol Cell 108(7):189–204
14. Dini L, Pagliara P, Emanuelia CC (2002) Phagocytosis of apoptotic cells by liver: A morphological study. Microsc Res Tech 57(6):530–540
15. Chemes H (1986) The Phagocytic Function of Sertoli Cells: A Morphological, Biochemical, and Endocrinological Study of Lysosomes and Acid Phosphatase Localization in the Rat Testis®. Endocrinology 119(4):1673–1681
16. Kevany BM, Palczewski K (2010) Phagocytosis of Retinal Rod and Cone Photoreceptors. Physiology 25(1):8–15
17. Feng W et al (2002) Merk Triggers Uptake of Photoreceptor Outer Segments during Phagocytosis by Cultured Retinal Pigment Epithelial Cells. J Biol Chem 277(19):17016–17022
18. Gal A et al (2000) Mutations in MERTK, the human orthologue of the RCS rat retinal dystrophy gene, cause retinitis pigmentosa. Nat Genet 26:270
19. Xiong W et al (2008) Gas6 and the Tyro 3 receptor tyrosine kinase subfamily regulate the phagocytic function of Sertoli cells. Reproduction 135(1):77–87
20. Guner D, Belka C, Daniel PT (2003) Disruption of cell death signaling in cancer: impact on disease prognosis and response to therapy. Curr Med Chem Anticancer Agents 3(5):319–326
21. Matzinger P (1994) Tolerance, Danger, and the Extended Family. Annu Rev Immunol 12(1):991–1045
22. Korias D et al (2011) Modulation of Macrophage Efferocytosis in Inflammation. Front Immunol 2:57
23. Ravichandran KS (2011) Beginnings of a Good Apoptotic Meal: The Find-Me and Eat-Me Signaling Pathways. Immunity 35(4):445–455
24. Elliott MR et al (2009) Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature 461:282
25. Truman LA et al (2008) CX3C1/4-fraclkin is released from apoptotic lymphocytes to stimulate macrophage chemotaxis. Blood 112(13):5026
26. Lauber K et al (2003) Apoptotic Cells Induce Migration of Phagocytes via Caspase-3-Mediated Release of a Lipid Attraction Signal. Cell 113(6):717–730
27. Gude DR et al (2008) Apoptosis induces expression of sphingosine kinase 1 to release sphingosine-1-phosphate as a “come-and-get-me” signal. FASEB J 22(8):2629–2638
28. Fadok VA et al (1992) Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol 148(7):2207
29. Borisenko GG et al (2003) Macrophage recognition of externalized phosphatidylserine and phagocytosis of apoptotic Jurkat cells—existence of a threshold. Arch Biochem Biophys 413(1):41–52
30. Park D et al (2007) BAI1 is an engulfment receptor for apoptotic cells upstream of the ELMO/Dock180/Rac module. Nature 450:430
31. Kobayashi N et al (2007) TIM-1 and TIM-4 glycoproteins bind phosphatidylserine and mediate uptake of apoptotic cells. Immunity 27(6):927–940
32. Park SY et al (2008) Rapid cell corpse clearance by stablin-2, a membrane phosphatidylserine receptor. Cell Death Differ 15(1):192
33. Morizono K et al (2011) The soluble serum protein Gas6 bridges virion envelope phosphatidylserine to the TAM receptor tyrosine kinase Axl to mediate viral entry. Cell Host Microbe 9(4):286–298
34. Hall MO et al (2005) Both protein S and Gas6 stimulate outer membrane phosphatidylserine and mediate uptake of apoptotic cells. J Immunol 148(7):2207
35. Fadok VA et al (1992) Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol 148(7):2207
36. Caberoy NB, Zhou Y, Li W (2010) Tubby and tubby-like protein 1 are new MerTK ligands for phagocytosis. EMBO J 29(23):3898–3910
37. Hafizi S, Dahlbäck B (2006) Gas6 and protein S. FEBS J 273(22):5231–5244
38. Akakura S et al (2004) The opsonin MFG-E8 is a ligand for the αβ5 integrin and triggers DOCK180-dependent Rac1 activation for the phagocytosis of apoptotic cells. Exp Cell Res 292(2):403–416
39. Elliott MR, Ravichandran KS (2016) The Dynamics of Apoptotic Cell Clearance. Dev Cell 38(2):147–160
40. Gardai SJ et al (2005) Cell-Surface Calreticulin Initiates Clearance of Viable or Apoptotic Cells through (em-trans-em)-Activation of LRP on the Phagocyte. Cell 123(2):321–334
41. Pâaïdassi H et al (2011) Investigations on the C1q-Calreticulin–Phosphatidylserine Interactions Yield New Insights into Apoptotic Cell Recognition. J Mol Biol 408(2):277–290
42. Brown S et al (2002) Apoptosis disables CD31-mediated cell detachment from phagocytes promoting binding and engulfment. Nature 418:200
43. Kojima Y et al (2016) CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis. Nature 536:86
44. Juncadella IJ et al (2012) Apoptotic cell clearance by bronchial epithelial cells critically influences airway inflammation. Nature 493:547
45. Ouimet M (2013) Autophagy in obesity and atherosclerosis: a molecular characterization of LC3-δ. Semin Immunopathol 35(5):429–453
46. Sanjuan MA et al (2007) Toll-like receptor signalling in macrophages links the autophagy pathway to phagocytosis. Nature 450:1253
47. Païdassi H et al (2011) Investigations on the C1q-Calreticulin–Phosphatidylserine Interactions Yield New Insights into Apoptotic Cell Recognition. J Mol Biol 408(2):277–290
48. Wu Y et al (2005) A role for Mer tyrosine kinase in alphavbeta5 integrin-mediated phagocytosis of apoptotic cells. J Cell Sci 118(Pt 3):539–553
49. Martinez J et al (2015) Requirement of DNase II for Definitive Erythropoiesis in the Mouse Fetal Liver. Science 292(5521):1546
50. Kojima Y et al (2016) CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis. Nature 536:86
51. Kawane K et al (2001) Requirement of DNase II for Definitive Erythropoiesis in the Mouse Fetal Liver. Science 292(5521):1546
52. Willingham SB et al (2012) The CD47-signal regulatory protein alpha (SIRPs) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci 109(17):6662
53. Weiskopf K et al (2013) Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies. Science 341(6141):88–91
54. Graham DK et al (2014) The TAM family: phosphatidylserine-sensing receptor tyrosine kinases gone awry in cancer. Nat Rev Cancer 14:769
55. Stach CM et al (2000) Treatment with annexin V increases immunogenicity of apoptotic human T-cells in Balb/c mice. Cell Death Differ 7:911
56. Bondanza A et al (2004) Inhibition of Phosphatidylserine Recognition Heightens the Immunogenicity of Irradiated Lymphoma Cells In Vivo. J Exp Med 200(9):1157
57. Linger RMA et al (2010) Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors. Expert Opin Ther Targets 14(10):1073–1090
58. Wu Y et al (2005) A role for Mer tyrosine kinase in alphavbeta5 integrin-mediated phagocytosis of apoptotic cells. J Cell Sci 118(Pt 3):539–553
59. Wang Y et al (2013) Mer receptor tyrosine kinase promotes invasion and survival in glioblastoma multiforme. Oncogene 32(7):872
60. Weiskopf K et al (2013) Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies. Science 341(6141):88–91
61. Graham DK et al (2014) The TAM family: phosphatidylserine-sensing receptor tyrosine kinases gone awry in cancer. Nat Rev Cancer 14:769
62. Wang Y et al (2013) Mer receptor tyrosine kinase promotes invasion and survival in glioblastoma multiforme. Oncogene 32(7):872
63. Sanjuan MA et al (2007) Toll-like receptor signalling in macrophages links the autophagy pathway to phagocytosis. Nature 450:1253
64. Kojima Y et al (2016) CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis. Nature 536:86
65. Juncadella IJ et al (2012) Apoptotic cell clearance by bronchial epithelial cells critically influences airway inflammation. Nature 493:547
66. Kojima Y et al (2016) CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis. Nature 536:86
67. Juncadella IJ et al (2012) Apoptotic cell clearance by bronchial epithelial cells critically influences airway inflammation. Nature 493:547
68. Kojima Y et al (2016) CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis. Nature 536:86
69. Kojima Y et al (2016) CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis. Nature 536:86
70. Kojima Y et al (2016) CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis. Nature 536:86
71. Kojima Y et al (2016) CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis. Nature 536:86
72. Kojima Y et al (2016) CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis. Nature 536:86
73. Kojima Y et al (2016) CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis. Nature 536:86
83. Lyons TR et al (2011) Postpartum mammary gland involution drives progression of ductal carcinoma in situ through collagen and COX-2. Nat Med 17(9):1109
84. McDaniel SM et al (2006) Remodeling of the mammary microenvironment after lactation promotes breast tumor cell metastasis. Am J Pathol 168(2):608–620
85. Schedin P et al (2007) Microenvironment of the involuting mammary gland mediates mammary cancer progression. J Mammary Gland Biol Neoplasia 12(1):71–82
86. DeRose P, Thorpe PE, Gerber DE (2011) Development of bavituximab, a vascular targeting agent with immune-modulating properties, for lung cancer treatment. Immunotherapy 3(8):933–944
87. Huang X, Bennett M, Thorpe PE (2005) A monoclonal antibody that binds anionic phospholipids on tumor blood vessels enhances the antitumor effect of docetaxel on human breast tumors in mice. Cancer Res 65(10):4408–4416
88. Beck AW et al (2006) Combination of a monoclonal anti-phosphatidylserine antibody with gemcitabine strongly inhibits the growth and metastasis of orthotopic pancreatic tumors in mice. Int J Cancer 118(10):2639–2643
89. He J et al (2009) Antiphosphatidylserine antibody combined with irradiation damages tumor blood vessels and induces tumor immunity in a rat model of glioblastoma. Clin Cancer Res 15(22):6871–6880
90. Chalasani P et al (2015) A phase I clinical trial of bavituximab and paclitaxel in patients with HER2 negative metastatic breast cancer. Cancer Med 4(7):1051–1059
91. Digumarti R et al (2014) Bavituximab plus paclitaxel and carboplatin for the treatment of advanced non-small-cell lung cancer. Lung Cancer 86(2):231–236
92. Yin Y et al (2013) Phosphatidylserine-targeting antibody induces M1 macrophage polarization and promotes myeloid-derived suppressor cell differentiation. Cancer Immunol Res 1(4):256–268
93. Byers L et al (2016) A phase I/II and pharmacokinetic study of BGB324, a selective AXL inhibitor as monotherapy and in combination with erlotinib in patients with advanced non-small cell lung cancer (NSCLC). Eur J Cancer 69:S18–S19
94. Zhang W et al (2014) UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor. J Med Chem 57(16):7031–7041
95. Cummings CT et al (2015) Small Molecule Inhibition of MERTK Is Efficacious in Non–Small Cell Lung Cancer Models Independent of Driver Oncogene Status. Mol Cancer Ther 14(9):2014–2022
96. DeRyckere D et al (2017) UNC2025, a MERTK small-molecule inhibitor, is therapeutically effective alone and in combination with methotrexate in leukemia models. Clin Cancer Res 23(6):1481–1492
97. Schroeder GM et al (2009) Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily. J Med Chem 52(5):1251–1254
98. Martinson Holly A et al (2014) Wound healing-like immune program facilitates postpartum mammary gland involution and tumor progression. Int J Cancer 136(8):1803–1813
99. Crittenden MR et al (2016) Mertk on tumor macrophages is a therapeutic target to prevent tumor recurrence following radiation therapy. Oncotarget 7(48):78653–78666